Literature DB >> 25206077

The mechanism of degeneration of striatal neuronal subtypes in Huntington disease.

Azadeh A Rikani1, Zia Choudhry2, Adnan M Choudhry3, Nasir Rizvi4, Huma Ikram5, Nusrat J Mobassarah6, Sagun Tulli7.   

Abstract

The pattern of neurodegeneration in Huntington's disease (HD) is very characteristic of regional locations as well as that of neuronal types in striatum. The different striatal neuronal populations demonstrate different degree of degeneration in response to various pathological events in HD. In the striatum, medium spiny GABA neurons (MSN) are preferentially degenerate while others are relatively spared. Vulnerability of specific neuronal populations within the striatum to pathological events constitutes an important hallmark of degeneration in HD. In an attempt to explain a likely mechanism of degeneration of striatal neuronal populations in HD, possible causes underlying differential vulnerability of neuronal subtypes to excitoxic insults and neurotrophic factors are discussed in this paper.

Entities:  

Keywords:  Huntington's Disease; MSN; NMDA

Year:  2014        PMID: 25206077      PMCID: PMC4158784          DOI: 10.5214/ans.0972.7531.210308

Source DB:  PubMed          Journal:  Ann Neurosci        ISSN: 0972-7531


Introduction

Huntington’s disease (HD) is a genetically dominant neurodegenerative condition characterized by progressive loss of motor and cognitive function that is caused by degeneration of selected neuronal populations within the basal ganglia and the cerebral cortex. HD is mainly driven by a genetic defect on chromosome 4 that results in an increase of repetition CAG (>39 CAG repeat to manifest disease) at the encoding site of huntingtin protein.[1] Profound effect in the degeneration of striatal projection neurons driven cognitive and motor impairments is the neuropathological signature of HD.[2,3] Based on this observation, term “selective neuronal vulnerability” is proposed by numbers of investigators (Table 1).[4] Overactivation of ionotropic glutamate receptors in response to endogenous or exogenous excitatory neurotransmitters via a pathological process that results in neuronal damage is well accepted as excitotoxicity phenomenon. Recent evidence suggests that excitotoxicity is one of the pathological pathways that is partly responsible for the degeneration of stratial neurons in HD.[3]
Table I:

Differential vulnerability of specific cell populations in HD and its relationship to morphological and biochemical characteristics

Anatomical locationCell typeRelative vulner-abilityMorphologyAfferentsTargetNT receptorsNTPeptidesOther molecular markers
J Neurochem. 2010 June; 113(5): 1073–1091.
StriatumMSN (direct pathway)+++projection neuron, long axonCortex (Glu), SNc (DA), Thalamus (Glu)GPi, SNrD1, NMDA, AMPAGABASubstance P/ DynorphinDARPP-32 GAD
MSN (direct pathway)+++++projection neuron, long axonCortex (Glu), SNc (DA), Thalamus (Glu)GPeD2, NMDA, AMPAGABAEnkephalinDARPP-32 GAD
Interneurons+extensive dendritic net-work, amon projects locallyMSNs, other interneuronsMSNs, other interneu-ronsD2, NMDA, AMPAAch.neuropetide Y, parvalbuminiNOS somatostatin
Cerebral CortexPyramidal neurons (layers V/VI)+++projection neuron, long axonThalamus, brainstem nucleiStriatum, brainstem, thalamusGlu, ACh, DA, NE, 5HTGlu-MAP2 CaMK
Interneurons+extensive dendritic network, axon projects locallyThalamusPyramidal neuronsGlu, GABAGABASomatostain, neuropeptide YGAD

Striatal histology

95% of the striatal neurons are projection neurons and only 5% are interneurons. Striatal projection neurons (also known as Golgi type I cells) are all GABAergic. They have long axon, medium-sized cell body and spiny dendrite. Interneurons are cholinergic and morphologically distinguished by a large soma and wide dendritic arborisation.

Differential expression of glutamate receptor subtypes and excitotoxic neurodegeneration

Glutamate is a well-known excitatory amino acid transmitter in the CNS. It activates both N-methyl-D-aspartate (NMDA) and non- NMDA ionotropic glutamate receptors. The critical role of glutamate receptors in mediating excitotoxic neuronal death in various neurodegenerative diseases is widely accepted.[5-8] Extensive studies show that abnormally sustained activation of NMDA receptors by glutamate can lead to prolonged increase in intracellular calcium via NMDA associated calcium channel.[9] Subsequently calcium dependent enzymes are activated and nitric oxide (NO) is synthesized. Neuronal nitric oxide synthase (nNOS) by itself triggers a cascade that stimulates neuronal damage. Although both medium sized spiny neurons (MSNs) and interneurons have NMDA receptors, there is an obvious difference between MSNs and interneurons in terms of expression of glutamate receptor subunits. Intrastriatal injection of agonists for NMDA (quinolinic acid) and non-NMDA (kainic acid) to animal model has shown higher vulnerability of MSNs to glutamate-induced excitotoxicity, compared to interneurons.[3,5] Lack of NMDA receptor subtype NR2B/NR2A in interneurons may make these cells less susceptible to excitotoxic insults. The second group of striatal interneurons are nicotinamide adenine dinucleotide phosphate (NADP) diaphorase positive that express very few NMDA receptors and are resistant to glutamate-induced excitotoxicity. Based on these observations, differential expression of glutamate receptor subtypes in striatal neuronal populations may participate in vulnerability of these cells to excitotoxic insults.

Selective protection of striatal neuronal subtypes by neurotrophic factors against excitotoxic insults.

Several protective mechanisms against different types of injuries exist in central nervous system. One of the mechanisms relies on neurotrophic factors that are involved in neuroprotection of neuronal cells. Among various neurotrophic factors in the striatum, members of neurotrophin and glial cell line derived neurotrophic factor (GDNF) are well known neurotrophic factors in striatum. Neurotrophic factors selectively protect specific neuronal populations against excitotoxic insults. Through useful experimental studies, engineered cells that released neurotrophins such as brain-derived neurotrophic factor (BDNF), NT-3, GDNF and neurturin were grafted in striatum before the intrastriatal injection of excitotoxic factors such as quinolinic acid or kainic acid. This study showed that BDNF and NT-3 equally protected both GABA/enkephalin and GABA/tackykinin positive neurons in striatum while GDNF and neurturin factors selectively protect striatal projection neurons of direct and indirect pathway, respectively. Cholinergic interneurons are only protected by GDNF.[10,11] Based on the result of this study, selective protection of neurotrophic factors could be due to differential vulnerability of striatal neuronal populations. Another useful experimental study showed that intrastriatal injection of quinolinic acid increased expression of nerve growth factor (NGF) mRNA le­vel while intrastriatal injection of Kainin acid induced expression of BDNF mRNA. Quinolinic acid and Kainin acid injection did not have any effect on expression of NT-3 (Fig. 1). Interestingly, down regulation of mRNA NT-3 was observed after intrastriatal injection of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA).[12] This study supports the hypothesis, which suggests that activation of glutamate receptors in striatum by different excitotoxicity amino acids preferentially regulate mRNA expression of neurotrophic factors. This specific expression may explain differential vulnerability of striatal neuronal subtypes to these factors.
Fig. 1:

Regulation of NGF mRNA levels by glutamate receptor agonists. Intrastriatal QUIN injection induced a continuous increase of NGF mRNA from 24 h until the last time examined (A). Increased levels of NGF mRNA were also observed 6 h after AMPA intrastriatal injury (C). No changes in NGF mRNA levels were obtained in KA- (B) or ACPD- (D) injected striatal. Triangles represent shaminjected striatal, whereas circle represent results from EAA injection. Values are represented as mean 6 SEM (*P, 0.05). Neurobiology of Disease 5, 357–364 (1998).

Regulation of NGF mRNA levels by glutamate receptor agonists. Intrastriatal QUIN injection induced a continuous increase of NGF mRNA from 24 h until the last time examined (A). Increased levels of NGF mRNA were also observed 6 h after AMPA intrastriatal injury (C). No changes in NGF mRNA levels were obtained in KA- (B) or ACPD- (D) injected striatal. Triangles represent shaminjected striatal, whereas circle represent results from EAA injection. Values are represented as mean 6 SEM (*P, 0.05). Neurobiology of Disease 5, 357–364 (1998).

Conclusion

Thus selective “vulnerability” of striatal neuronal populations to excitatory neurotransmitters and neurotrophic factors may constitute the mechanism underlying unique pattern of striatal degeneration in HD. The differential distribution of glutamate receptors and subunits in striatal neurons may alter vulnerability of striatal neuronal populations to excitotoxins. Recent studies also indicate that differential vulnerability of striatal neuronal subtypes to neurotrophic factors depends on level of expression of these factors and their receptors that are transiently up or down regulated through the activation of glutamate receptors. Since neurotrophic factors have a special characteristic to selectively protect striatal neuronal subtypes against excitoxic insults, they may be considered as a preventative and therapeutic approach for HD.
  11 in total

1.  Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea.

Authors:  J T Coyle; R Schwarcz
Journal:  Nature       Date:  1976-09-16       Impact factor: 49.962

Review 2.  Neuronal degeneration in striatal transplants and Huntington's disease: potential mechanisms and clinical implications.

Authors:  Francesca Cicchetti; Denis Soulet; Thomas B Freeman
Journal:  Brain       Date:  2011-01-28       Impact factor: 13.501

Review 3.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

4.  Nerve cell lesions caused by 3-hydroxyglutaric acid: a possible mechanism for neurodegeneration in glutaric acidaemia I.

Authors:  B Flott-Rahmel; C Falter; P Schluff; R Fingerhut; E Christensen; C Jakobs; U Musshoff; J D Fautek; T Deufel; A Ludolph; K Ullrich
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

5.  Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo.

Authors:  E Pérez-Navarro; J Alberch; I Neveu; E Arenas
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

6.  Neuropathological, biochemical and molecular findings in a glutaric acidemia type 1 cohort.

Authors:  Christopher B R Funk; Asuri N Prasad; Patrick Frosk; Sven Sauer; Stefan Kölker; Cheryl R Greenberg; Marc R Del Bigio
Journal:  Brain       Date:  2005-02-02       Impact factor: 13.501

Review 7.  Producing striatal phenotypes for transplantation in Huntington's disease.

Authors:  Sophie V Precious; Anne E Rosser
Journal:  Exp Biol Med (Maywood)       Date:  2012-04-04

8.  Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease.

Authors:  J M Canals; S Marco; N Checa; A Michels; E Pérez-Navarro; E Arenas; J Alberch
Journal:  Neurobiol Dis       Date:  1998-11       Impact factor: 5.996

9.  Ketamine-induced neuronal damage and altered N-methyl-D-aspartate receptor function in rat primary forebrain culture.

Authors:  Fang Liu; Tucker A Patterson; Natalya Sadovova; Xuan Zhang; Shuliang Liu; Xiaoju Zou; Joseph P Hanig; Merle G Paule; William Slikker; Cheng Wang
Journal:  Toxicol Sci       Date:  2012-10-11       Impact factor: 4.849

10.  Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration.

Authors:  F Cicchetti; S Saporta; R A Hauser; M Parent; M Saint-Pierre; P R Sanberg; X J Li; J R Parker; Y Chu; E J Mufson; J H Kordower; T B Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-20       Impact factor: 11.205

View more
  20 in total

1.  Huntington's disease brain-derived small RNAs recapitulate associated neuropathology in mice.

Authors:  Jordi Creus-Muncunill; Anna Guisado-Corcoll; Veronica Venturi; Lorena Pantano; Georgia Escaramís; Marta García de Herreros; Maria Solaguren-Beascoa; Ana Gámez-Valero; Cristina Navarrete; Mercè Masana; Franc Llorens; Daniela Diaz-Lucena; Esther Pérez-Navarro; Eulàlia Martí
Journal:  Acta Neuropathol       Date:  2021-02-06       Impact factor: 17.088

Review 2.  Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy.

Authors:  Ling Liu; Jin-Sha Huang; Chao Han; Guo-Xin Zhang; Xiao-Yun Xu; Yan Shen; Jie Li; Hai-Yang Jiang; Zhi-Cheng Lin; Nian Xiong; Tao Wang
Journal:  Mol Neurobiol       Date:  2015-12-10       Impact factor: 5.590

3.  Effects of Deltamethrin Acute Exposure on Nav1.6 Channels and Medium Spiny Neurons of the Nucleus Accumbens.

Authors:  Cynthia M Tapia; Oluwarotimi Folorunso; Aditya K Singh; Kathleen McDonough; Fernanda Laezza
Journal:  Toxicology       Date:  2020-05-06       Impact factor: 4.221

Review 4.  Endocannabinoid system in neurodegenerative disorders.

Authors:  Balapal S Basavarajappa; Madhu Shivakumar; Vikram Joshi; Shivakumar Subbanna
Journal:  J Neurochem       Date:  2017-07-05       Impact factor: 5.372

Review 5.  Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntington's and Parkinson's Disease.

Authors:  Talita Glaser; Roberta Andrejew; Ágatha Oliveira-Giacomelli; Deidiane Elisa Ribeiro; Lucas Bonfim Marques; Qing Ye; Wen-Jing Ren; Alexey Semyanov; Peter Illes; Yong Tang; Henning Ulrich
Journal:  Neurosci Bull       Date:  2020-10-07       Impact factor: 5.203

6.  Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease.

Authors:  Giovanni Luca; Ilaria Bellezza; Iva Arato; Alba Di Pardo; Francesca Mancuso; Mario Calvitti; Giulia Falabella; Sara Bartoli; Vittorio Maglione; Enrico Amico; Mariagrazia Favellato; Giuseppe Basta; Maria Bodo; Alba Minelli; Riccardo Calafiore; Luigi Frati; Ferdinando Squitieri
Journal:  CNS Neurosci Ther       Date:  2016-05-26       Impact factor: 5.243

7.  The Potential Regulatory Mechanisms of miR-196a in Huntington's Disease through Bioinformatic Analyses.

Authors:  Mu-Hui Fu; Chia-Ling Li; Hsiu-Lien Lin; Shaw-Jeng Tsai; Yen-Yu Lai; Yu-Fan Chang; Pei-Hsun Cheng; Chuan-Mu Chen; Shang-Hsun Yang
Journal:  PLoS One       Date:  2015-09-16       Impact factor: 3.240

8.  Real-time imaging of Huntingtin aggregates diverting target search and gene transcription.

Authors:  Li Li; Hui Liu; Peng Dong; Dong Li; Wesley R Legant; Jonathan B Grimm; Luke D Lavis; Eric Betzig; Robert Tjian; Zhe Liu
Journal:  Elife       Date:  2016-08-03       Impact factor: 8.140

Review 9.  Applications of Induced Pluripotent Stem Cells in Studying the Neurodegenerative Diseases.

Authors:  Wenbin Wan; Lan Cao; Bill Kalionis; Shijin Xia; Xiantao Tai
Journal:  Stem Cells Int       Date:  2015-07-09       Impact factor: 5.443

Review 10.  Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding.

Authors:  Svetlana A Ivanova; Anton J M Loonen
Journal:  Parkinsons Dis       Date:  2016-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.